Celldex Therapeutics, Inc.CLDXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
38.59%
↑ 341% above average
Average (9y)
8.74%
Historical baseline
Range
High:44.79%
Low:-35.78%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | 38.59% |
| 2023 | 43.46% |
| 2022 | 44.79% |
| 2021 | 40.16% |
| 2020 | -5.01% |
| 2019 | -35.78% |
| 2018 | -30.91% |
| 2017 | -6.38% |
| 2016 | 2.55% |
| 2015 | -4.03% |